Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00423059
Status:
COMPLETED
Last Update Posted:
2007-03-13
First Post:
2007-01-16
Brief Title:
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
Histologic Changes of Fibrovascular Membrane Associated With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab Avastin
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Recently intravitreal bevacizumab Avastin injection has gained popularity as a potential treatment of intraocular neovascularization CNV associated with age related macular degeneration and diabetic retinopathy The efficacy of the drug is thought to be related with its pharmacologic blockade of VEGF
The purpose of this study is to determine the effect of the intravitreal bevacizumab on the fibrovascular membrane associated with proliferative diabetic retinopathy by objective histologic evaluation
The patients scheduled for vitrectomy for tractional fibrovascular membrane due to proliferative diabetic retinopathy will be randomized into two treatment groups The one will receive conventional vitrectomy and the other group will receive intravitreal bevacizumab injection one week before the scheduled vitrectomy The fibrovascular membrane will be excised during surgery and fixated for histologic examinations The expression of VEGF and PEDF a potent inhibitor of angiogenesis will be evaluated in the fibrovascular membrane by immunohistochemistry The results will be compared between two treatment groups
The purpose of this study is to determine the effect of the intravitreal bevacizumab on the fibrovascular membrane associated with proliferative diabetic retinopathy by objective histologic evaluation
The patients scheduled for vitrectomy for tractional fibrovascular membrane due to proliferative diabetic retinopathy will be randomized into two treatment groups The one will receive conventional vitrectomy and the other group will receive intravitreal bevacizumab injection one week before the scheduled vitrectomy The fibrovascular membrane will be excised during surgery and fixated for histologic examinations The expression of VEGF and PEDF a potent inhibitor of angiogenesis will be evaluated in the fibrovascular membrane by immunohistochemistry The results will be compared between two treatment groups
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None